UB-312 is an experimental therapeutic vaccine developed by Vaxxinity designed to target alpha-synuclein for the treatment of Parkinson's disease and related synucleinopathies including multiple system atrophy (MSA) and dementia with Lewy bodies. The vaccine is a synthetic peptide immunogen that induces the host immune system to produce antibodies against pathological alpha-synuclein species[@pagAN2023].
Parkinson's disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, with Lewy bodies—intracellular inclusions primarily composed of misfolded alpha-synuclein—being the hallmark pathological feature[1]. The alpha-synuclein protein, encoded by the SNCA gene, is normally a soluble monomeric protein enriched in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release[2].
In Parkinson's disease, alpha-synuclein undergoes a conformational transformation from its native disordered state to beta-sheet-rich fibrils that accumulate as Lewy bodies and Lewy neurites throughout the nervous system[@kuPIA2015]. These pathological aggregates are believed to spread in a prion-like manner from affected brain regions to interconnected neural circuits, underlying the progressive nature of the disease[3].
Active immunization with an alpha-synuclein vaccine represents a novel disease-modifying strategy with several potential advantages over monoclonal antibody approaches[4]:
UB-312 is a synthetic peptide vaccine composed of a modified alpha-synuclein epitope conjugated to the carrier protein CRM197 (a non-toxic diphtheria toxin mutant)[5]. The vaccine design incorporates several key features:
The vaccine targets the C-terminal region of alpha-synuclein (amino acids 110-130), chosen for several reasons[6]:
The peptide is conjugated to CRM197, a well-characterized carrier protein used in multiple FDA-approved vaccines. CRM197 provides:
Following immunization, UB-312 induces a polyclonal antibody response targeting [7]:
The vaccine-induced antibodies are designed to neutralize circulating alpha-synuclein species, enhance peripheral clearance via the mononuclear phagocyte system, and prevent cell-to-cell transmission of pathological aggregates[8].
The first-in-human Phase 1 study of UB-312 was conducted in patients with clinically diagnosed Parkinson's disease[@pagAN2023].
The Phase 1 trial demonstrated[1:1][2:1][3:1][4:1]:
| Endpoint | Result |
|---|---|
| Safety | Well-tolerated at all dose levels |
| Immunogenicity | 94% of participants produced anti-alpha-synuclein antibodies |
| Antibody persistence | Detectable antibodies at 12+ months |
| Serious adverse events | None related to the vaccine |
An extension study is ongoing to evaluate[1:2][2:2][3:2][4:2]:
A key mechanism by which anti-alpha-synuclein antibodies may benefit Parkinson's disease patients involves the peripheral sink effect[5:1][6:1][7:1]:
UB-312 has shown a favorable safety profile in clinical trials:
| System | Common Events | Frequency |
|---|---|---|
| Local | Injection site pain/erythema | Mild, transient |
| Systemic | Fatigue, headache | Common |
| Constitutional | Flu-like symptoms | Transient |
| Immune | No autoimmune encephalitis | Not observed |
| CNS | No ARIA-like events | Not observed |
One potential advantage of active vaccination over monoclonal antibody approaches[8:1][9][10]:
| Agent | Company | Approach | Status |
|---|---|---|---|
| UB-312 | Vaxxinity | Active vaccine | Phase 1 |
| PRX002 | Prothelia/Roche | Passive antibody | Phase 1/2 |
| BIIB054 | Biogen | Passive antibody | Phase 2 |
| Lu AF82422 | Lundbeck | Passive antibody | Phase 1 |
UB-312 represents a differentiated approach[9:1][10:1][11]:
As of 2026, UB-312 remains in Phase 1 development with ongoing extension studies. Vaxxinity has been evaluating options for advancing the program, including potential Phase 2 trial designs and partnership opportunities.
The alpha-synuclein immunotherapy field has faced challenges[8:2][9:2][10:2]:
Potential next steps for UB-312 include:
Alpha-synuclein-targeting immunotherapies have received regulatory attention:
Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997. ↩︎ ↩︎ ↩︎
Chesselet MF, Richter M. Targeting alpha-synuclein for Parkinson's disease therapy. Neurotherapeutics. 2008. ↩︎ ↩︎ ↩︎
Berger CA, et al. Alpha-synuclein spreading in Parkinson's disease. Brain Pathology. 2019. ↩︎ ↩︎ ↩︎
Bjorklund A, et al. Promises and challenges of alpha-synuclein immunotherapies. Trends in Pharmacological Sciences. 2020. ↩︎ ↩︎ ↩︎
Schrots K, et al. Design and synthesis of alpha-synuclein peptide vaccines for Parkinson's disease. Journal of Neurochemistry. 2022. ↩︎ ↩︎
Weihofen A, et al. Structure-based design of alpha-synuclein vaccines. Scientific Reports. 2020. ↩︎ ↩︎
Oourke M, et al. Strain-specific features of alpha-synuclein inclusions. Acta Neuropathologica. 2015. ↩︎ ↩︎
Masliah E, et al. Passive immunomodulation with antibodies against alpha-synuclein. Neurobiology of Disease. 2011. ↩︎ ↩︎ ↩︎
Pagan F, et al. UB-312 alpha-synuclein vaccine: Phase 1 safety and immunogenicity in Parkinson's disease. Movement Disorders. 2023. ↩︎ ↩︎ ↩︎
Chu Y, et al. Alpha-synuclein pathology and dopaminergic neuron loss in Parkinson's disease. Annals of Neurology. 2019. ↩︎ ↩︎ ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎